LioCyx-M004

N/A

Report date: 2026/04/08 15:32:27

Base Information

Drug NameLioCyx-M004
Drug Alias Name抗HCC个性化HBV特异性TCR-T细胞疗法autologous T-cells transfected with HBV antigenspecific TCRs (hepatocellular carcinoma)T-cell receptor directed T-cell therapyLiocyx-DPersonalized HBV specific TCR-T cell therapy against HCC +[11] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Gene therapy > mRNACell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionAnti-HBsAgHuman leukocyte antigen modulators
TargetsHepatitis B Surface AntigensHuman leukocyte antigen
Therapy Area/IndicationsCarcinoma, HepatocellularHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Lion TCR Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLion Tcr Pte LtdGuangzhou Lion TCR Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, HepatocellularHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A